Brief: An2 Therapeutics Inc - Enters Open Market Sale Agreement With Jefferies For Up To $80 Million Common Stock - SEC Filing
09/04/2026 23:04
April 9 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS INC - ENTERS OPEN MARKET SALE AGREEMENT WITH JEFFERIES FOR UP TO $80 MILLION COMMON STOCK - SEC FILING AN2 THERAPEUTICS INC - TERMINATES TD COWEN SALES AGREEMENT EFFECTIVE APRIL 9, 2026 - SEC FILING AN2 THERAPEUTICS INC - SOLD 2.5 MILLION SHARES FOR ABOUT $20 MILLION UNDER TD COWEN SALES AGREEMENT PRIOR TO TERMINATION - SEC FILING Source text: [ID:n0001193125-26-149822] Further company coverage: ANTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview